Dissemin is shutting down on January 1st, 2025

Published in

Bohn Stafleu van Loghum, Critical Care, 1(25), 2021

DOI: 10.1186/s13054-020-03452-x

Links

Tools

Export citation

Search in Google Scholar

Ketamine in acute phase of severe traumatic brain injury “an old drug for new uses?”

Journal article published in 2021 by Daniel Agustin Godoy, Rafael Badenes ORCID, Paolo Pelosi, Chiara Robba
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractMaintaining an adequate level of sedation and analgesia plays a key role in the management of traumatic brain injury (TBI). To date, it is unclear which drug or combination of drugs is most effective in achieving these goals. Ketamine is an agent with attractive pharmacological and pharmacokinetics characteristics. Current evidence shows that ketamine does not increase and may instead decrease intracranial pressure, and its safety profile makes it a reliable tool in the prehospital environment. In this point of view, we discuss different aspects of the use of ketamine in the acute phase of TBI, with its potential benefits and pitfalls.